JAK/STAT Signaling

inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase

EGFR inhibitor

AZD3759 (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively.

Selective ErbB2 inhibitor

Mutant EGFR inhibitor, potent and irreversible

STAT3 inhibitor

inhibits IL-6-mediated JAK/STAT signal transduction

Cucurbitacin I is a selective Janus Kinase (JAK)/STAT3 signaling pathway inhibitor with an IC 50 value of 500nM in A549.

STAT5 Inhibitor is a STAT5 inhibitor with an IC50 of 47 μM for STAT5β isoform.

Genistein, a precursor of phytoalexins in legumes, is an important nutraceutical molecule found in soybean seeds.

EGFR activator

STAT inhibitor

AG 99 ((E)-Tyrphostin 46) is a potent EGFR inhibitor.

NSC 74859 is a selective STAT3 inhibitor with an IC 50 of 86μM.

SH-4-54 is a specific STAT3 inhibitor with a K D of 300 nM. It is commonly used in the study of treatments for brain cancers such as glioblastoma.

Pacritinib (SB1518) (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib (SB1518) also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).

Colivelin (CLN) is A brain-permeable neuroprotective peptide that has effective long-term effects on Aβ deposition, neuronal apoptosis and synaptic plasticity defects in neurodegenerative diseases.

BTK-specific tyrosine kinase inhibitor

Novel Janus kinase inhibitor

HER2 inhibitor

Olmutinib (HM61713, BI 1482694) (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib (HM61713, BI 1482694) is used for NSCLC.

p300 inhibitor

agent for the treatment of most tapeworm infections

ErbB receptor family tyrosine kinase inhibitor